Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

The Composite Health Risk Assessment Model (CHARM) to Predict 1-Year Non-Relapse Mortality (NRM) Among Older Recipients of Allogeneic Transplantation: A Prospective BMT-CTN Study 1704

Blood (2023) 142 (Supplement 1): 109.

https://doi.org/10.1182/blood-2023-173855

Published: 2023

Journal Articles

Impact of Autologous Hematopoietic Cell Transplant (HCT) Followed By Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance in Increasing Multiple Myeloma (MM) Immunity (BMT CTN 1401)

Blood (2021) 138 (Supplement 1): 899.

https://doi.org/10.1182/blood-2021-149659

Published: 2021

Journal Articles

Durable Remission of Refractory and Advanced Stage Mycosis Fungoides/Sezary Syndrome (MF/SS) Utilizing an "Outpatient" Alemtuzumab and Fludarabine-Based Reduced Intensity Allogeneic Peripheral Blood Stem Cell Transplantation (PBSCT)

Phuong Vo, Ramaprasad Srinivasan, Enkhtsetseg Purev, MD PhD, Emily McDuffee, Lisa Cook, Tatyana Worthy, Geri Hawks, Prince Patricia, Reem Shalabi, Brian Wells, Robert Reger, MS, Hanh Khuu, David Stroncek, Xin Tian, PhD, Nancy Geller, Georg Aue, Richard Childs, MD

Blood (2017) 130 (Supplement 1): 1962.

https://doi.org/10.1182/blood.V130.Suppl_1.1962.1962

Published: 2017

Journal Articles

Comparison of Autologous Hematopoietic Cell Transplant (autoHCT), Bortezomib, Lenalidomide (Len) and Dexamethasone (RVD) Consolidation with Len Maintenance (ACM), Tandem Autohct with Len Maintenance (TAM) and Autohct with Len Maintenance (AM) for up-Front Treatment of Patients with Multiple Myeloma (MM): Primary Results from the Randomized Phase III Trial of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN 0702 - StaMINA Trial)

Blood (2016) 128 (22): LBA-1.

https://doi.org/10.1182/blood.V128.22.LBA-1.LBA-1

Published: 2016

Journal Articles

Results of a Phase III Randomized, Multi-Center Study of Allogeneic Stem Cell Transplantation after High Versus Reduced Intensity Conditioning in Patients with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML): Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0901

Blood (2015) 126 (23): LBA-8.

https://doi.org/10.1182/blood.V126.23.LBA-8.LBA-8

Published: 2015

Journal Articles

Tandem Autologous Hematopoietic Stem Cell Transplants (AuHCT) with or without Maintenance Therapy (auto-auto) Versus Single AuHCT Followed by HLA Matched Sibling Non- Myeloablative Allogeneic HCT (auto-allo) for Patients with Standard Risk (SR) Multiple Myeloma (MM): Results From the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0102 Trial

Blood (2010) 116 (21): 41.

https://doi.org/10.1182/blood.V116.21.41.41

Published: 2010

Journal Articles

Long-Term Follow-up of Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Severe Paroxysmal Nocturnal Hemoglobinuria

Jeremy Pantin, MD, Xin Tian, Nancy Geller, PhD, Catalina Ramos, CRN, Lisa Cook, CRN, Sophia Grasmeder, CRN, Philip Scheinberg, MD, Neal S. Young, MD, Sumithira Vasu, MD, Theresa Donohue, MHS, PA-C, Richard Childs, MD

Blood (2010) 116 (21): 3505.

https://doi.org/10.1182/blood.V116.21.3505.3505

Published: 2010

Journal Articles

Absence of Graft Failure and Excellent Long Term Survival Following Fludarabine-Based Reduced Intensity Hematopoietic Stem Cell Transplantation In Heavily Transfused Patients with ATG-Refractory Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes

Jeremy Pantin, MD, Xin Tian, Ph.D., Nancy Geller, Ph.D., Catalina Ramos, CRN, Lisa Cook, CRN, Sophia Grasmeder, CRN, Philip Scheinberg, MD, Neal S. Young, MD, Sumithira Vasu, MD, Theresa Donohue, MHS, PA-C, Richard Childs, MD

Blood (2010) 116 (21): 517.

https://doi.org/10.1182/blood.V116.21.517.517

Published: 2010

Journal Articles

Tandem Autologous Stem Cell Transplants (auto-auto) with or without Maintenance Therapy Versus Single Autologous Transplant Followed by HLA-Matched Sibling Non- Myeloablative Allogeneic Stem Cell Transplant (auto-allo) for Patients (pts) with High Risk (HR) Multiple Myeloma (MM): Results From the Blood and Marrow Transplant Clinical Trials Network (BMT-CTN) 0102 Trial

Blood (2010) 116 (21): 526.

https://doi.org/10.1182/blood.V116.21.526.526

Published: 2010

Journal Articles

Biologic Assignment Clinical Trials in Hematopoietic Stem Cell Transplantation (HSCT) for Multiple Myeloma: Baseline Characteristics by Treatment Allocation from BMT CTN 0102 According to Availability of an HLA-Matched Sibling Donor.

Marcelo C. Pasquini, MD, MS, Marian Ewell, PhD, Edward A. Stadtmauer, MD, Christopher N. Bredeson, MD, MSc, FRCPC, Edwin P. Alyea, MD, Keith Stockerl-Goldstein, MD, Amrita Krishnan, MD, Firoozeh Sahebi, MD, Scott D. Rowley, MD, David G. Maloney, MD, David H. Vesole, MD, PhD, Mary M. Horowitz, MD, MS, Shelly Carter, PhD, Nancy Geller, PhD, Sergio Giralt, MD, Blood Marrow Transplant Clinical Trials Network (BMT CTN)

Blood (2007) 110 (11): 3028.

https://doi.org/10.1182/blood.V110.11.3028.3028

Published: 2007

Journal Articles

Reduced Incidence of Acute Graft Versus Host Disease (GVHD) and Transplant-Related Mortality (TRM) with the Addition of Short-Course Mini-Dose Methotrexate (MTX) to Cyclosporine (CSA) as GVHD Prophylaxis Following Nonmyeloablative Hematopoietic Stem Cell Transplantation (NST).

Ramaprasad Srinivasan, Haley Hedlin, Rose Goodwin, Aleah Smith, Catalina Ramos, Lisa Cook, Charles Bolan, Hisayuki Yokoyama, Shivani Srivastava, Jennifer Karpovich, Teresa Donohue, John Barrett, Nancy Geller, Richard Childs

Blood (2007) 110 (11): 2990.

https://doi.org/10.1182/blood.V110.11.2990.2990

Published: 2007

Journal Articles

A Pilot Study Evaluating the CD34+ Cell Mobilizing Activity and Adverse Events Associated with Escalating Doses of AMD3100 in Healthy Volunteers.

Steven J. Lemery, MD, Matthew M. Hsieh, MD, Aleah Smith, Sheila Rao, Hanh M. Khuu, Donohue Theresa, PA, Jennifer M. Karpovich, NP, Lisa Cook, RN, Rose Goodwin, RN, Carol Boss, MPH, Gary Calandra, Nancy Geller, PhD, John Tisdale, MD, Richard Childs, MD

Blood (2007) 110 (11): 3278.

https://doi.org/10.1182/blood.V110.11.3278.3278

Published: 2007

Journal Articles

High Response Rates in Acute Steroid Refractory Graft-Versus-Host Disease (GVHD) Following Combined Tumor Necrosis Factor-alpha (TNF-α) and Interleukin-2 (IL-2) Blockade.

Ramaprasad Srinivasan, MD, PhD, Nancy Geller, PhD, Colleen Dorrance, MD, Igor Espinoza-Delgado, MD, A. John Barrett, MD, Yoshiyuki Takahashi, MD, PhD, Richard W. Childs, MD

Blood (2005) 106 (11): 1801.

https://doi.org/10.1182/blood.V106.11.1801.1801

Published: 2005

Journal Articles

Evaluation of Three Different Cyclosporine-Based Graft Versus Host Disease (GVHD) Prophylaxis Regimens Following Nonmyeloablative Hematopoietic Stem Cell Transplantation (NST).

Ramaprasad Srinivasan, MD, PhD, Nancy Geller, PhD, Sakti Chakrabarti, MD, Igor Espinoza-Delgado, MD, Teresa Donohue, Susan Leitman, MD, Charles D. Bolan, MD, Elizabeth J. Read, MD, John A. Barrett, MD, Richard W. Childs, MD

Blood (2004) 104 (11): 1236.

https://doi.org/10.1182/blood.V104.11.1236.1236

Published: 2004

Journal Articles

Prior chemotherapy and allograft CD34 + dose impact donor engraftment following nonmyeloablative allogeneic stem cell transplantation in patients with solid tumors

Cristian Carvallo, Nancy Geller, Roger Kurlander, Ramaprasad Srinivasan, Othon Mena, Takehito Igarashi, Linda M. Griffith, W. Marston Linehan, Richard W. Childs

Blood (2004) 103 (4): 1560–1563.

https://doi.org/10.1182/blood-2003-04-1170

Published: 2004

NARROW

The Composite Health Risk Assessment Model (CHARM) to Predict 1-Year Non-Relapse Mortality (NRM) Among Older Recipients of Allogeneic Transplantation: A Prospective BMT-CTN Study 1704

Impact of Autologous Hematopoietic Cell Transplant (HCT) Followed By Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance in Increasing Multiple Myeloma (MM) Immunity (BMT CTN 1401)

Durable Remission of Refractory and Advanced Stage Mycosis Fungoides/Sezary Syndrome (MF/SS) Utilizing an "Outpatient" Alemtuzumab and Fludarabine-Based Reduced Intensity Allogeneic Peripheral Blood Stem Cell Transplantation (PBSCT)

Results of a Phase III Randomized, Multi-Center Study of Allogeneic Stem Cell Transplantation after High Versus Reduced Intensity Conditioning in Patients with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML): Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0901

Long-Term Follow-up of Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Severe Paroxysmal Nocturnal Hemoglobinuria

Absence of Graft Failure and Excellent Long Term Survival Following Fludarabine-Based Reduced Intensity Hematopoietic Stem Cell Transplantation In Heavily Transfused Patients with ATG-Refractory Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes

Biologic Assignment Clinical Trials in Hematopoietic Stem Cell Transplantation (HSCT) for Multiple Myeloma: Baseline Characteristics by Treatment Allocation from BMT CTN 0102 According to Availability of an HLA-Matched Sibling Donor.

Reduced Incidence of Acute Graft Versus Host Disease (GVHD) and Transplant-Related Mortality (TRM) with the Addition of Short-Course Mini-Dose Methotrexate (MTX) to Cyclosporine (CSA) as GVHD Prophylaxis Following Nonmyeloablative Hematopoietic Stem Cell Transplantation (NST).

A Pilot Study Evaluating the CD34+ Cell Mobilizing Activity and Adverse Events Associated with Escalating Doses of AMD3100 in Healthy Volunteers.

High Response Rates in Acute Steroid Refractory Graft-Versus-Host Disease (GVHD) Following Combined Tumor Necrosis Factor-alpha (TNF-α) and Interleukin-2 (IL-2) Blockade.

Evaluation of Three Different Cyclosporine-Based Graft Versus Host Disease (GVHD) Prophylaxis Regimens Following Nonmyeloablative Hematopoietic Stem Cell Transplantation (NST).

Prior chemotherapy and allograft CD34 + dose impact donor engraftment following nonmyeloablative allogeneic stem cell transplantation in patients with solid tumors

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only